GE HealthCare Technologies Inc. (NASDAQ:GEHC) specializes in hospital imaging, including MRI, CT, and ultrasound machines, and the contrast agents required to interpret scans. Spun out of General Electric in early 2023, GE HealthCare traded near its 52-week low of $58.75 and 28% below its high of $89.77, at a closing price of $64.81 on September 21, 2026. On September 22, Needham initiated coverage on the stock with a Buy rating and a $93 price target, representing roughly 44% potential upside. The firm argues that market skepticism has created an attractive valuation.
Why It Fell So Far
The stock’s decline is driven by a few headwinds. Primarily, sales stalled in China, which represents roughly 13% of company revenue, owing to tough competition from local rivals and tightened Chinese hospital budgets. Additionally, import tariffs raised costs, and GEHC took a $245 million hit to operating profit from tariffs in 2025 before some were refunded. Another headwind is the tight hospital budgets that led healthcare providers to delay capital spending on expensive medical scanners. Together, these headwinds made the steady device maker look like a company with a growth problem.
The Bull Case
The bulls focus on demand and recurring revenue. Trading near 15x earnings, GE HealthCare is priced below its peers despite dealing with imaging that hospitals cannot operate without. The company is adding AI tools that make scans faster and sharper, which supports pricing power. In addition, hospitals continuously reorder its contrast agents and radiopharmaceuticals for daily patient procedures, unlike a scanner bought once a decade. GEHC is also in talks to buy Sofie Biosciences for about $1 billion, which is expected to further expand this high-margin imaging portfolio.
DON’T MISS: GE HealthCare (GEHC) Reportedly Eyes $1B Sofie Deal. What Would Ownership Add?
The Bear Case
The bear thesis believes the cheap price is deserved. Market share losses to domestic manufacturers in China could prove difficult to reclaim. And at the same time, tariffs and trade tensions keep the costs unpredictable. Furthermore, demand for costly scanners remains sensitive to general hospital capital budgets. Institutional ownership reflects this divided sentiment. Insider Monkey database records 59 hedge funds holding GEHC in the second quarter of 2026, roughly flat with 60 in the prior quarter.
The Bottom Line
GE HealthCare Technologies Inc.’s debate centers on the significant question of whether China and tariff damage are short-term adjustments or lasting market share losses. The bullish thesis stands on steady demand for diagnostic scans, AI upgrades, and a deal that adds repeat sales. The bears, on the other hand, see a company losing ground in a key market with costs it cannot fully control. The next earnings report, alongside any further developments on the Sofie deal, could tilt the scale in favor of a bear or a bull.
READ NEXT: Equity LifeStyle (ELS) Slides Near 52-Week Lows: Can Core Rental Stability Offset Higher Rates? and Constellation (STZ) Brands Hit a 52-Week Low. Is the Corona-and-Modelo Machine Broken, or On Sale?
